Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1
Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses
Promotion of Th17 polarized immunity via co-delivery of Mincle agonist and Tuberculosis antigen using silica nanoparticles
Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses
Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD
Diamino allose phosphates: Novel, potent, and highly stable Toll-like receptor 4 agonists
Self-adjuvanting TLR7/8 agonist and fentanyl hapten co-conjugate achieves enhanced protection against fentanyl challenge
A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models
B. Crouse et al.
A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice
S.M. Miller et al.
